How Smart Investors Look at UiPath (PATH).

UiPath logged a -4.8% change during today's afternoon session, and is now trading at a price of $23.48 per share. The S&P 500 index moved -0.0%. PATH's trading volume is 13,341,987 compared to the stock's average volume of 8,516,695.

UiPath trades 1.03% away from its average analyst target price of $23.24 per share. The 17 analysts following the stock have set target prices ranging from $17.0 to $30.0, and on average have given UiPath a rating of buy.

If you are considering an investment in PATH, you'll want to know the following:

  • UiPath has moved 87.0% over the last year, and the S&P 500 logged a change of 17.0%

  • Based on its trailing earnings per share of -0.27, UiPath has a trailing 12 month Price to Earnings (P/E) ratio of -87.0 while the S&P 500 average is None

  • PATH has a forward P/E ratio of 45.2 based on its forward 12 month price to earnings (EPS) of $0.52 per share

  • The company has a price to earnings growth (PEG) ratio of 1.14 — a number near or below 1 signifying that UiPath is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 6.79 compared to its sector average of None

  • UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan.

  • Based in New York, the company has 3,833 full time employees and a market cap of $13.29 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.